Clinical Trial Update: Immunogenicity of ND1.1 by Delivery Directly to the Ileum [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the immunogenicity of ND1.1 delivered directly to the ileum for Avian influenza has completed. The study was sponsored by Vaxart.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• ND1.1

Snippet

Sponsor: Vaxart | Conditions: Avian Influenza | Phase 1 | Status: COMPLETED